Targeting tumor endothelial cells with nanoparticles

Yu Sakurai, Hidetaka Akita, Hideyoshi Harashima

Research output: Contribution to journalReview articlepeer-review

31 Citations (Scopus)


Because angiogenesis is a major contributor to cancer progression and metastasis, it is an attractive target for cancer therapy. Although a diverse number of small compounds for anti-angiogenic therapy have been developed, severe adverse effects commonly occur, since small compounds can affect not only tumor endothelial cells (TECs), but also normal endothelial cells. This low selectivity for TECs has motivated researchers to develop alternate types of drug delivery systems (DDSs). In this review, we summarize the current state of knowledge concerning the delivery of nano DDSs to TECs. Their payloads range from small compounds to nucleic acids. Perspectives regarding new therapeutic targets are also mentioned.

Original languageEnglish
Article number5819
JournalInternational Journal of Molecular Sciences
Issue number23
Publication statusPublished - 2019 Dec 1


  • Anti-angiogenic therapy
  • Drug delivery system
  • Nanoparticles
  • Nucleic acids
  • Tumor endothelial cells


Dive into the research topics of 'Targeting tumor endothelial cells with nanoparticles'. Together they form a unique fingerprint.

Cite this